Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 199

Results For "X"

9466 News Found

India’s opportunity to build preventive healthcare economy
Opinion | May 19, 2026

India’s opportunity to build preventive healthcare economy

The country’s strength lies not just in technology availability but in adoption behaviour


HAB Pharma, Signature Phytochemicals merge to form Rs. 600 crore integrated pharma entity
News | May 19, 2026

HAB Pharma, Signature Phytochemicals merge to form Rs. 600 crore integrated pharma entity

Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026


Alivus Life Sciences posts steady FY26 growth as margins surge past guidance
News | May 19, 2026

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26


Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer
Biopharma | May 19, 2026

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs


Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare
interviews | May 18, 2026

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Access to genomic testing, not therapy cost, is the biggest challenge


Lupin launches Atharv ability neuro-rehabilitation centre in Delhi
News | May 18, 2026

Lupin launches Atharv ability neuro-rehabilitation centre in Delhi

New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches


Strides Pharma reports  Rs. 2,489.7 crore revenue during FY26, 2% YoY growth
Biopharma | May 18, 2026

Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth

Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore